XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.38% | -13.30% | -19.98% | -26.26% | -19.14% |
| Depreciation & Amortization | -2.84% | 0.81% | -4.27% | -5.46% | -0.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.18% | -12.85% | -2.93% | -14.87% | -23.87% |
| Operating Income | 16.18% | 12.85% | 2.93% | 14.87% | 23.87% |
| Income Before Tax | -98.80% | -178.54% | 19.83% | -163.83% | -26.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.80% | -178.54% | 19.83% | -163.83% | -26.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.80% | -178.54% | 19.83% | -163.83% | -26.83% |
| EBIT | 16.18% | 12.85% | 2.93% | 14.87% | 23.87% |
| EBITDA | 14.07% | 11.54% | 1.80% | 14.33% | 24.48% |
| EPS Basic | -1.46% | -80.64% | 55.49% | -1,211.04% | -8.03% |
| Normalized Basic EPS | -1.42% | -80.54% | 55.52% | -1,210.74% | -8.02% |
| EPS Diluted | -1.53% | -80.78% | 55.45% | -1,212.76% | -7.52% |
| Normalized Diluted EPS | -1.42% | -80.54% | 55.52% | -1,210.74% | -8.02% |
| Average Basic Shares Outstanding | 93.01% | 72.78% | 64.40% | 52.97% | 46.87% |
| Average Diluted Shares Outstanding | 93.01% | 72.78% | 64.40% | 52.97% | 46.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |